Canada markets open in 4 hours 59 minutes

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.02+0.12 (+2.03%)
At close: 04:00PM EDT
5.86 -0.16 (-2.66%)
Pre-Market: 04:25AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

    —Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment – Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 2022, allowing the trial to begin – Top-line findings from the second phase of the Phase 1/2 HERA trial show that the primary endpoint for safety was met in the randomized placebo-controlled portion of the study –$27 million in cash, cash equivalents and s

  • GlobeNewswire

    Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022

    Live conference call on Friday, August 12 at 8:30 a.m. ESTMIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2022 financial results on Friday, August 12, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss t

  • GlobeNewswire

    Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)

    MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer’s Disease (AD) has been accepted for a poster presentation at the Alzheimer’s Association International Conference (AAIC), being held July 31-August 4, 2022 in San Diego, California, as well as virtually. “We are pleas